Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Total XV - Total therapy study XV for newly diagnosed patients with acute lymphoblastic leukaemia.

Trial Profile

Total XV - Total therapy study XV for newly diagnosed patients with acute lymphoblastic leukaemia.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anthracyclines; Asparaginase; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Mercaptopurine; Methotrexate; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms Total-XV
  • Most Recent Events

    • 11 Sep 2020 Biomarkers information updated
    • 25 Apr 2011 Planned end date changed from 1 Nov 2010 to 1 Nov 2020 as reported by ClinicalTrials.gov.
    • 20 Dec 2010 Further results, from a subgroup of older adolescents, have been reported early online in the Clinical Journal of Oncology, according to a St Jude's media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top